Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of B-cell driven, autoimmune systemic vasculitides characterized by a relapsing course and the presence of ANCA autoantibodies which are instrumental in their pathogenesis. We aimed to investigate autoreactive proteinase 3 (PR3+) B cells involved in the development of human AAV. We previously developed a customized flow-cytometry method to identify autoreactive B cells among cryopreserved peripheral blood mononuclear cells (PBMC), using labeled PR3, one of the main AAV autoantigens, as a ligand. We therefore used multicolor flow cytometry in combination with bioinformatics and functional in vitro studies on 1) baseline samples of PBMC from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-ANCA+ AAV (PR3-AAV) and myeloperoxidase (MPO)-AAV, and 27 healthy controls (HC); 2) samples of matched bone marrow (BM) and peripheral blood from 8 non-vasculitis patients; and 3) 148 longitudinal samples from 23 PR3-AAV patients of the RAVE trial. Clinical data and outcomes from the trial and medical records were correlated with PR3+ B cells (total and subsets). In brief, we identified and phenotypically characterized autoreactive B cells in AAV and healthy controls, reporting their perturbations among the different B cell subsets, and their functional ability to produce PR3-ANCA autoantibodies in vivo and in vitro. We reported their maturation through central and peripheral tolerance checkpoints from BM to peripheral blood, leading to an accumulation of atypical autoreactive PR3+ memory B cells in PR3-AAV patients but not in MPO-AAV and HC. We also described the longitudinal association between autoreactive plasmablast redetection after anti-B cell 13 targeted therapy with the main disease outcome, relapse. Overall, our findings suggest the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients in PR3-AAV, elucidating the selection process of autoreactive B cells, and their association with disease relapse.

Autoreactive B Cells in ANCA-Associated Vasculitis / Berti, Alvise. - (2021 Dec 22), pp. 1-170. [10.15168/11572_325394]

Autoreactive B Cells in ANCA-Associated Vasculitis

Berti, Alvise
2021-12-22

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of B-cell driven, autoimmune systemic vasculitides characterized by a relapsing course and the presence of ANCA autoantibodies which are instrumental in their pathogenesis. We aimed to investigate autoreactive proteinase 3 (PR3+) B cells involved in the development of human AAV. We previously developed a customized flow-cytometry method to identify autoreactive B cells among cryopreserved peripheral blood mononuclear cells (PBMC), using labeled PR3, one of the main AAV autoantigens, as a ligand. We therefore used multicolor flow cytometry in combination with bioinformatics and functional in vitro studies on 1) baseline samples of PBMC from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-ANCA+ AAV (PR3-AAV) and myeloperoxidase (MPO)-AAV, and 27 healthy controls (HC); 2) samples of matched bone marrow (BM) and peripheral blood from 8 non-vasculitis patients; and 3) 148 longitudinal samples from 23 PR3-AAV patients of the RAVE trial. Clinical data and outcomes from the trial and medical records were correlated with PR3+ B cells (total and subsets). In brief, we identified and phenotypically characterized autoreactive B cells in AAV and healthy controls, reporting their perturbations among the different B cell subsets, and their functional ability to produce PR3-ANCA autoantibodies in vivo and in vitro. We reported their maturation through central and peripheral tolerance checkpoints from BM to peripheral blood, leading to an accumulation of atypical autoreactive PR3+ memory B cells in PR3-AAV patients but not in MPO-AAV and HC. We also described the longitudinal association between autoreactive plasmablast redetection after anti-B cell 13 targeted therapy with the main disease outcome, relapse. Overall, our findings suggest the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients in PR3-AAV, elucidating the selection process of autoreactive B cells, and their association with disease relapse.
22-dic-2021
XIV
2019-2020
CIBIO (29/10/12-)
Biomolecular Sciences
Grandi, Guido
Ulrich Specks – Mayo Clinic, Rochester (MN, USA) Divi Cornec – University of Brest (France)
no
Inglese
File in questo prodotto:
File Dimensione Formato  
00000000. FINAL VERSION 11202021.pdf

Open Access dal 16/12/2023

Tipologia: Tesi di dottorato (Doctoral Thesis)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 5.57 MB
Formato Adobe PDF
5.57 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/325394
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact